cell lymphoma A new prognostic index (MIPI) for patients with advanced-stage mantle

doi:10.1182/blood-2007-06-095331Prepublished online October 25, 2007;2008 111: 558-565€€€€Eimermacher, Hannes Wandt, Joerg Hasford, Wolfgang Hiddemann and Michael UnterhaltPeter, Wolfram Jung, Bernhard Wormann, Wolf-Dieter Ludwig, Ulrich Duhrsen, HartmutKluin-Nelemans, Michael Pfreundschuh, Marcel Reiser, Bernd Metzner, Hermann Einsele, Norma Eva Hoster, Martin Dreyling, Wolfram Klapper, Christian Gisselbrecht, Achiel van Hoof, Hanneke C.€

[1]  E. Hoster,et al.  Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas , 2006, Cancer.

[2]  B. Christensen,et al.  Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index , 2006, British journal of haematology.

[3]  Douglas G Altman,et al.  Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.

[4]  P. Solal-Céligny.  Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.

[5]  L. Sehn.  Optimal use of prognostic factors in non-Hodgkin lymphoma. , 2006, Hematology. American Society of Hematology. Education Program.

[6]  W. Klapper,et al.  Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network , 2005, British journal of haematology.

[7]  E. Hoster,et al.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Hoster,et al.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.

[9]  G. Brittinger,et al.  Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome , 2004, Leukemia.

[10]  W. Sauerbrei,et al.  Validation of existing and development of new prognostic classification schemes in node negative breast cancer , 2004, Breast Cancer Research and Treatment.

[11]  R. Champlin,et al.  Long‐term follow‐up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission , 2003, Cancer.

[12]  K. Franssila,et al.  Ki‐67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma , 2002, European journal of haematology.

[13]  P. de Nully Brown,et al.  A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. , 2002, European journal of cancer.

[14]  J. Habbema,et al.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. , 2001, Journal of clinical epidemiology.

[15]  Douglas G Altman,et al.  Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.

[16]  W. Chan,et al.  Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group , 2000, American journal of hematology.

[17]  A. López-Guillermo,et al.  Mantle cell lymphoma , 1998, Seminars in hematology.

[18]  G. Salles,et al.  Mantle cell lymphoma: a retrospective study of 121 cases , 1998, Leukemia.

[19]  K. Franssila,et al.  Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. , 1998, European journal of cancer.

[20]  S. Koscielny,et al.  Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 cases. , 1997, Leukemia & lymphoma.

[21]  R. Gascoyne,et al.  Mantle cell lymphoma: a clinicopathologic study of 80 cases. , 1997, Blood.

[22]  E. Noordijk,et al.  Mantle-cell lymphoma: a population-based clinical study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Cavalli,et al.  Patterns of survival in mantle cell lymphoma. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[25]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[26]  W. Sauerbrei,et al.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.

[27]  R. Tibshirani,et al.  An Introduction to the Bootstrap , 1995 .

[28]  S. Pileri,et al.  Mantle Cell Lymphoma , 2022, The EBMT/EHA CAR-T Cell Handbook.

[29]  P. Grambsch,et al.  Martingale-based residuals for survival models , 1990 .

[30]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[31]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[32]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[33]  K. Lennert,et al.  Cytological and functional criteria for the classification of malignant lymphomata. , 1975, The British journal of cancer. Supplement.

[34]  Jacob Cohen,et al.  Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. , 1968 .